Please login to the form below

Not currently logged in
Email:
Password:

KRAS mutation

This page shows the latest KRAS mutation news and features for those working in and with pharma, biotech and healthcare.

Boehringer Ingelheim forms ‘virtual research’ alliance with MD Anderson

Boehringer Ingelheim forms ‘virtual research’ alliance with MD Anderson

Mutations in the KRAS pathway have been recognised for decades as a key part of oncology research. ... In June this year, Amgen reported safety, tolerability and preliminary anti-tumour activity in a phase 1 trial of a candidate which targets a KRAS

Latest news

  • Has Amgen cracked KRAS? First clinical data says maybe Has Amgen cracked KRAS? First clinical data says maybe

    It is estimated that around 14% of NSCLC adenocarcinoma patients and roughly 5% of colorectal cancer patients have the KRAS G12C mutation. ... The KRAS G12C mutation has emerged as a clear front-runner among the various targets for pharmacological

  • So far so good for Amgen's much-anticipated KRAS inhibitor So far so good for Amgen's much-anticipated KRAS inhibitor

    The KRAS G12C mutation is present in approximately 14% of non-small cell lung adenocarcinomas and 5% of colorectal cancers, with a 1%-3% rate in other solid tumours. ... Amgen is in a race with Mirati Therapeutics to bring a KRAS G12C inhibitor through

  • AZ's selumetinib stumbles at last fence in lung cancer AZ's selumetinib stumbles at last fence in lung cancer

    NSCLC) whose tumours tested positive for the KRAS mutation in the SELECT-1 trial. ... KRAS is one of the most common mutations seen in NSCLC - occurring in around a third of patients - and typically causes adenocarcinoma tumours that are associated with

  • AstraZeneca moves MEK inhibitor selumetinib into phase III AstraZeneca moves MEK inhibitor selumetinib into phase III

    The drug is being investigated with docetaxel as a second-line treatment for NSCLC tumours that are KRAS mutation positive, a sub-type of lung cancer associated with poor prognosis and ... in combination with chemotherapy is superior to chemotherapy

  • Personal treatment

    The US National Comprehensive Cancer Network and the American Society of Clinical Oncology now strongly recommend genetic screening for the KRAS mutation in metastatic colorectal cancer patients before prescribing either treatment. ... Genetic profiling

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    This includes people with NSCLC who have a mutated KRAS gene - an area where no specific treatment option exists. ... With selumetinib you've now got that plus another 20-25 per cent of NSCLC cases - people with the KRAS mutation.”.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics